New and innovative technologies for controlling Non-Compressible Haemorrhages are being sought by Research and Clinical Innovation (RCI) Research, Surgeon General's Department
- DASA has launched a new Market Exploration called 'Non-Compressible Haemorrhage - Novel Technologies'
- This Market Exploration is being run on behalf of Research and Clinical Innovation (RCI) Research, Surgeon General's Department
- The deadline for submissions is midday (BST) on 15 April 2025
The Defence and Security Accelerator (DASA) is pleased to launch a new Market Exploration around Non-Compressible Haemorrhage (NCH) to understand who is doing work in this area and to uncover novel solutions for treating NCH at a combat casualty scene. Run on behalf of Research and Clinical Innovation (RCI) Research , Surgeon General's Department, this Market Exploration is seeking to identify existing technologies from Technology Readiness Level (TRL) 3 and above. This will allow a better understanding of the current market capability to inform future medical research, treatment and development.
Non-Compressible Haemorrhage refers to bleeding from anatomical structures that cannot be controlled, or only partially controlled, with application of external pressure, undertaken through an overlying tourniquet or direct manual pressure. Such bleeding is the chief cause of otherwise preventable battlefield death. NCH is highly lethal with a mortality rate of 85%
Do you work in this area? Could your innovation be used in a novel way? Read the full Market Exploration document and submit a proposal.
What technologies is this Market Exploration seeking?
The RCI Research, Surgeon General's Department is seeking options of treating NCH at the emergency scene that can be used by non-medical professionals in austere settings close to point of injury.
In particular, the exploration should focus on medical device technologies that can target or triage the source of haemorrhage in the pre-hospital environment, from bodily cavity through to exact organ or vessel. Refinements of current medical devices, transfusion of blood or other infusion fluids, and pharmacologic means of haemostasis or haemorrhage control will be out-of-scope for this exploration.
Ideally, the proposed solution should be portable, simple to use and go well beyond the current limits of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA), Abdominal Tourniquet, or expanding foam. For instance, it could be applicable to haemorrhage within the thoracic cavity or the retroperitoneal areas of the abdomen. However, it should not compromise other aspects of care and follow-on surgery or require excessive resource to control, apply or remove.
